AdaptHealth (AHCO)
(Delayed Data from NSDQ)
$9.08 USD
+0.42 (4.85%)
Updated Aug 7, 2024 04:00 PM ET
After-Market: $9.08 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value A Growth A Momentum A VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
AHCO 9.08 +0.42(4.85%)
Will AHCO be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for AHCO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for AHCO
AdaptHealth Corp. (AHCO) Beats Q2 Earnings and Revenue Estimates
Myriad Genetics (MYGN) Expands in MRD Testing With New Collab
AHCO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Implied Volatility Surging for AdaptHealth (AHCO) Stock Options
AHCO or PBH: Which Is the Better Value Stock Right Now?
Asensus Surgical (ASXC) Inks a Merger Agreement With KARL STORZ
Other News for AHCO
AdaptHealth (AHCO) Receives a Buy from Truist Financial
Buy Rating Affirmed for AdaptHealth on Strong Q2 Performance and Strategic Growth Initiatives
AdaptHealth Analysis: Hold Rating Amidst Revised Guidance and Financial Headwinds
AHCO Stock Earnings: AdaptHealth Beats EPS, Beats Revenue for Q2 2024
Palantir, Uber report Q2 beats: Morning Buzz